Drug Policy Watch · State Brief 2026

Arizona

Snapshot (structured)

Adult-use cannabis: Legal since 2020 (Prop 207), retail sales since Jan 2021
Medical cannabis: Legal since 2010 (Arizona Medical Marijuana Act)
Home grow: Yes, up to 6 plants per adult (12 per household)
Intoxicating hemp / hemp THC: Banned outside the licensed dispensary system per 2024 AG opinion
Psychedelics: Not decriminalized; research-and-advisory posture (psilocybin advisory board, ibogaine research funding)
Broad decriminalization: No (no general drug decriminalization)
Harm reduction: Syringe services and fentanyl test strips legal since 2021; broad naloxone access
Governor (party): Katie Hobbs (Democrat)
Legislature control: Republican (Senate 17-13, House 33-27)
Citizen ballot initiatives allowed: Yes
Enclosure pressure score: 4/5

Cannabis

Adult-use cannabis has been legal in Arizona since voters passed Proposition 207, the Smart and Safe Arizona Act, in November 2020, with licensed adult-use retail sales beginning in January 2021. Adults 21 and older may possess up to one ounce (no more than five grams of which may be concentrate). Medical cannabis has been legal since 2010 under the voter-approved Arizona Medical Marijuana Act, and registered patients retain advantages including higher possession limits and an exemption from the 16 percent adult-use excise tax. (Tucson Weekly, Ballotpedia, MPP Arizona)

Home cultivation is allowed: adults may grow up to six plants for personal use, with a cap of twelve plants per household where two or more adults reside. (Zenleaf Arizona)

Market structure: Arizona uses a vertically integrated license model in which a single marijuana establishment license entitles the holder to cultivation, manufacturing, and retail operations. The state caps the number of these licenses at roughly 169 statewide, a deliberately tight cap that concentrates ownership. Multi-state operators (MSOs) have a substantial presence in the Arizona market. The adult-use excise tax is 16 percent on top of standard state and local transaction privilege (sales) tax. Arizona surpassed 1 billion dollars in cumulative marijuana tax revenue (medical plus adult-use) in March 2025; that revenue flows into the Smart and Safe Arizona Fund. (IndicaOnline, MJBizDaily social equity, AZ Dept of Revenue, ArizonaStateCannabis tax)

Key 2026 actions: The dominant cannabis development was a proposed citizen initiative to repeal most of Prop 207's commercial market (see Ballot initiatives), filed in December 2025 and abandoned in May 2026. The legislature also advanced a measure expanding nuisance law to treat excessive marijuana smoke and odor as grounds for declaring a residential property a nuisance (status unconfirmed as to final enactment; see Active legislation). Delivery of adult-use marijuana by licensed dispensaries and approved third parties became legal in late 2024. (AZ Capitol Times, AZ Cannabis News)

Hemp

Arizona effectively prohibits intoxicating hemp-derived products outside its licensed marijuana dispensary system. A 2024 Arizona Attorney General opinion (I24-005 / R24-001) concluded that products synthesized from hemp to be intoxicating, including delta-8, delta-10, HHC, THCP, and similar cannabinoids, cannot be legally sold outside the tightly regulated dispensary framework; within dispensaries these are sold as marijuana, not hemp. Non-intoxicating hemp products such as CBD oils, tinctures, and topicals remain legal to buy, possess, and ship into the state with no medical card and no state possession limit. (AZ AG opinion, Burning Daily, ProCannabis, Cannabis Regulations AI)

A 2025 pro-hemp regulatory bill, SB1702 (hemp-derived products; regulation), backed by the Hemp Industry Trade Association of Arizona, sought to create a structured retail framework for hemp products but failed to advance and is listed as dead. (LegiScan SB1702, TrackBill SB1702, U.S. Hemp Roundtable)

Federal exposure: Federal spending legislation enacted in late 2025 narrows the federal definition of hemp to cap total THC (not just delta-9) at 0.3 percent on a dry weight basis, with the change taking effect roughly one year out, around November 12, 2026. This closes the loophole that allowed high-delta-8, delta-10, and THCA products to qualify as hemp. Because Arizona already restricts intoxicating hemp at the state level, the practical retail effect of the federal change is smaller here than in permissive states, but it will pressure any remaining gray-market sales and the in-state hemp industry. Reporting frames the federal ban as giving Arizona's hemp businesses about a year to adapt. (Perkins Coie, Regulatory Oversight, Phoenix New Times, AZFamily)

Psychedelics

Arizona has not decriminalized psilocybin or other psychedelics, and possession, manufacture, and sale remain prohibited. The state's posture is research and advisory rather than access. In 2025 the legislature passed SB1555, signed into law (Chapter 231, June 27, 2025), establishing a state Psilocybin Advisory Board under the Department of Health Services to review the science on psilocybin for conditions such as depression, anxiety, and addiction and to publish reports. SB1555 explicitly does not legalize or decriminalize psilocybin. Separately, HB2871 was signed into law, appropriating 5 million dollars from the general fund in FY2025-2026 to DHS for a grant to fund a clinical research study on ibogaine for neurological conditions including traumatic brain injury and PTSD. (LegiScan SB1555, AZLeg SB1555 signed summary, Marijuana Moment psychedelics, Reason ibogaine, LegiScan HB2871)

A more ambitious effort to license psilocybin service centers (a Sen. T. J. Shope vehicle, SB1287 in 2025) cleared the Senate in March 2025 in a 23-4 vote but was significantly amended in committee, with the central service-center licensing provisions stripped out before passage. An earlier 2024 version with regulated-access components intact passed both chambers but was vetoed by Governor Hobbs, who said the evidence did not yet support widespread clinical expansion. 2026 standalone service-center legislation status is unconfirmed; check the live tracker. (Marijuana Moment Senate passage, Marijuana Moment House panel, LegiScan SB1287, Harris Sliwoski)

Broader drug policy

Arizona has no broad drug decriminalization; possession of controlled substances remains criminalized.

Harm reduction: Arizona legalized syringe services programs and fentanyl test strips in 2021. SB1250 (signed by then-Governor Ducey) authorizes cities, towns, counties, and nongovernmental organizations to operate overdose and disease-prevention programs including sterile syringe access and naloxone distribution. SB1486, signed May 18, 2021, removed penalties on fentanyl and other drug-checking test strips; both took effect in late September 2021. Naloxone is broadly available: under a standing order from the Arizona Department of Health Services, pharmacists may dispense it to any Arizona resident. (AZPHA, AZPM needle exchange, LegiScan SB1250, Filter, AHCCCS naloxone)

Sentencing and expungement: Prop 207 created a pathway to petition for expungement (record sealing) of certain marijuana offenses beginning July 12, 2021, including possession of 2.5 ounces or less, cultivation of six or fewer plants, and possession of paraphernalia. This is petition-based, not automatic. (MPP Arizona, Zenleaf Arizona)

Overdose and treatment policy: The Arizona Health Care Cost Containment System (AHCCCS, the state Medicaid agency) and county health departments fund naloxone distribution, fentanyl test strip access, diversion programs, and treatment and recovery services. Maricopa County and others run substance use programs. (Maricopa County, AHCCCS naloxone)

Political landscape

Governor: Katie Hobbs (Democrat). Legislature: Republican-controlled, with a 17-13 Senate majority and a 33-27 House majority, producing divided government in which Hobbs holds veto power. (Ballotpedia 2026 session, Wikipedia 57th Legislature, Copper Courier)

Reform champions: Sen. T. J. Shope (R) has been the leading legislative champion of regulated psilocybin access, repeatedly carrying service-center legislation. Sen. Christine Marsh (D) championed the 2021 fentanyl test strip legalization after losing her son to an accidental overdose. (Marijuana Moment, DB Phoenix)

Opponents: Sean Noble, founder of American Encore, led the 2025-2026 effort to repeal Arizona's commercial adult-use market via citizen initiative; he abandoned the effort in May 2026 and walked back claims about youth marketing. Governor Hobbs has acted as a brake on psychedelics expansion, vetoing the 2024 psilocybin service-center bill on evidentiary grounds. Key committee assignments for drug policy in the 2026 session are unconfirmed; check azleg.gov committee rosters. (Marijuana Moment repeal, NORML)

Ballot initiatives

Arizona allows citizen-initiated ballot measures (initiated statutes and constitutional amendments); Prop 207 and the 2010 medical act were both citizen initiatives. The marijuana measures themselves are entrenched: because they were enacted by voters, the Voter Protection Act sharply limits the legislature's ability to amend or repeal them.

For 2026, the notable measure was the Arizona Repeal Marijuana Legalization Initiative (the Sensible Marijuana Policy Act for Arizona, serial number I-04-2026), filed by Sean Noble of American Encore on December 17, 2025. It would have repealed most of Prop 207's commercial framework, banning recreational dispensaries, cultivation, manufacturing, testing labs, commercial sales, and cannabis taxes, while leaving personal possession of up to one ounce and home cultivation of up to six plants legal and not touching medical marijuana. It required 255,949 valid signatures by July 3, 2026. The campaign was abandoned in May 2026 and will not appear on the November 3, 2026 ballot. (Ballotpedia, AZ Capitol Times, Cannabis Business Times, MJBizDaily)

Equity and expungement

Social-equity licensing: Prop 207 directed the state to create a social equity ownership program. The Arizona Department of Health Services awarded 26 social equity licenses by lottery in April 2022, drawing 1,506 applicants. The program has been widely criticized as captured: reporting and litigation indicate that corporate investors and operators came to control nearly all of the 26 licenses, with as few as three original winners retaining a stake, often through predatory financing and option agreements signed before licenses issued. SB1262 (2024) attempted to address predatory agreements; subsequent reform legislation to investigate and return improperly obtained licenses to original winners has been introduced. Social equity applicants paid a reduced 5,000 dollar application fee versus the standard 25,000 dollars and had to meet three of four hardship criteria (prior prohibition enforcement impact, residency in one of 87 qualifying ZIP codes, a family member with a marijuana conviction, or low household income). (MJBizDaily 26 licenses, Marijuana Moment grab, AZCIR, MJBizDaily reform failure)

Expungement: Petition-based expungement of qualifying marijuana offenses has been available since July 12, 2021 under Prop 207. It is not automatic, so individuals must affirmatively file; this excludes people who do not know about the process or lack legal help. (MPP Arizona, Zenleaf Arizona)

Market and barriers

Adult-use excise tax: 16 percent, on top of state and local transaction privilege (sales) tax. (AZ Dept of Revenue)
Cumulative marijuana tax revenue: surpassed 1 billion dollars by March 2025 (medical plus adult-use). (ArizonaStateCannabis)
License cap: roughly 169 vertically integrated marijuana establishment licenses statewide. (IndicaOnline)
Social equity licenses: 26 total, awarded by lottery in 2022. (MJBizDaily)
Application fees: standard 25,000 dollars; social equity reduced to 5,000 dollars. (Marijuana Moment)
Annual renewal fees and precise capital/residency requirements: not fully confirmed here; verify with ADHS rules. The vertically integrated model itself imposes high capital barriers because a licensee must stand up cultivation, manufacturing, and retail.

Enclosure read

Arizona is a heavily fenced cannabis market. The structural choices, a hard cap near 169 vertically integrated licenses, mandatory vertical integration, and a ban on intoxicating hemp outside the licensed system, all push toward consolidation and favor well-capitalized multi-state operators over small and independent entrants. The social equity program, intended to widen ownership, was substantially captured by investors and corporate operators, with nearly all 26 equity licenses ending up under outside control and only a handful of original winners retaining a stake. Home growers and personal-possession users retain meaningful rights (six plants, one ounce), which is the main offsetting decentralizing feature, and the 2026 repeal threat that would have abolished the commercial market while preserving home grow was abandoned. Hemp entrepreneurs are largely fenced out by the AG opinion and the coming federal THC cap. On balance this is a consolidated, fenced market with a protected personal-use carve-out, scoring 4/5. It is not a 5 because possession and home cultivation remain genuinely open and the licensed market is large and competitive among the operators inside the fence. (IndicaOnline, Marijuana Moment, AZ AG opinion)

What to watch next

November 12, 2026 (approximate): federal hemp redefinition takes effect, capping total THC at 0.3 percent and squeezing the remaining intoxicating-hemp trade in Arizona. (Perkins Coie)
July 3, 2026: signature deadline that the now-abandoned Prop 207 repeal initiative would have faced; relevant because a future repeal effort could re-emerge for 2028. (Ballotpedia)
Psilocybin Advisory Board outputs: the board was to be seated by late 2025 and meet at least every two months, with reports that could shape future access legislation; watch for whether Sen. Shope refiles service-center legislation in 2027. (LegiScan SB1555)
Ibogaine grant: DHS process to award the 5 million dollar FY2025-2026 clinical research grant. (Phoenix New Times)
Legislative calendar: the 2026 regular session adjourned in mid-June 2026; the next regular session (first regular session of the 58th Legislature) is expected to convene in January 2027. (AZ Mirror, Ballotpedia 2026 session)

Regulators

Cannabis (medical and adult-use): Arizona Department of Health Services (ADHS), which licenses and regulates marijuana establishments and the medical patient program. (Zenleaf Arizona)
Cannabis taxation: Arizona Department of Revenue (ADOR), which administers the 16 percent adult-use excise tax and transaction privilege tax. (AZ Dept of Revenue)
Hemp: Arizona Department of Agriculture (industrial hemp program) plus the Attorney General's enforcement posture on intoxicating hemp. (AZ AG opinion)
Psychedelics research and harm reduction: Arizona Department of Health Services (psilocybin advisory board, ibogaine grant, naloxone standing order). Medicaid and treatment funding flows through AHCCCS. (LegiScan SB1555, AHCCCS)

Federal exposure (2026)

Cannabis remains Schedule I by default under federal law. A DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational adult-use cannabis stays Schedule I. The practical Arizona effect is split by program. Arizona's medical marijuana businesses, operating under the voter-approved Arizona Medical Marijuana Act and licensed by ADHS, fall within the state-licensed medical category and thus shed the Internal Revenue Code Section 280E deduction disallowance for that medical activity, with Treasury also asked to consider retrospective 280E relief; in exchange they face a fast-track DEA registration regime carrying Schedule III recordkeeping, security, disposal, and labeling obligations. Arizona's adult-use operators get no direct relief: their recreational revenue stays Schedule I and 280E continues to bite. Because Arizona runs a vertically integrated, MSO-heavy market in which a single license spans cultivation, manufacturing, and retail, almost every Arizona operator runs both a medical and an adult-use book under one roof. The split treatment therefore rewards the larger, well-capitalized players who can credibly carve out, document, and DEA-register their medical operations to capture the 280E benefit, while small operators face the cost and complexity of compliance described in coverage as a federal compliance cliff that arrives before full relief does. A broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; even full Schedule III would not legalize cannabis, would not authorize interstate commerce, and would not cover Arizona's recreational businesses. (Foley Hoag, Duane Morris, Benesch Law, WeedPress compliance cliff)

The November 12, 2026 hemp cliff bears directly on Arizona. FY2026 agriculture appropriations (Section 781, sponsored by Rep. Andy Harris, R-MD) narrow the federal definition of hemp to a total-THC standard of roughly 0.4 milligrams of THC per container, recriminalizing about 90 to 95 percent of intoxicating hemp products effective November 12, 2026; a delay bill, H.R. 7010 (unconfirmed; Congress.gov), was not enacted, and the 2026 Farm Bill, H.R. 7567 (unconfirmed; Congress.gov), keeps the ban. Arizona already bans intoxicating hemp outside the licensed dispensary system per the 2024 AG opinion (I24-005 / R24-001), so the practical retail effect in-state is muted: the products the federal cliff targets are already supposed to be sold only inside dispensaries as marijuana, not on convenience-store shelves as hemp. The federal change mainly removes the interstate supply and manufacturing rationale that propped up any remaining Arizona gray-market and online-shipped intoxicating-hemp trade, and it forecloses the path SB1702 (2025, dead) would have opened toward a separate legal hemp retail tier. Non-intoxicating CBD remains legal to buy, possess, and ship into Arizona. (Perkins Coie, Regulatory Oversight, Phoenix New Times, AZ AG opinion)

Banking exposure stays acute. SAFER Banking has stalled in Congress, so Arizona's licensed cannabis operators remain locked out of routine federally regulated banking, payment processing, and lending, forcing cash-heavy operations and elevated security and tax burdens. This compounds the consolidation pressure already built into Arizona's tight license cap and mandatory vertical integration: an MSO-heavy market with deep capital can self-finance and absorb cash-management costs, while undercapitalized and social-equity operators cannot. The April 2026 Schedule III order for medical cannabis does not by itself open banking; it eases 280E for the medical category but leaves the federal banking framework unchanged. (Foley Hoag updates)

Psychedelics exposure is conditional and forward-looking. Psilocybin, MDMA, and ibogaine remain Schedule I federally. An April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review of psychedelic therapies, but there is no FDA approval yet, and conditional federal rescheduling triggers only on approval. Arizona's posture is research-and-advisory only, the SB1555 Psilocybin Advisory Board and the HB2871 ibogaine clinical research grant, so federal fast-tracking is largely complementary rather than disruptive here: Arizona is positioned to feed and benefit from the federal research pipeline, and an eventual FDA approval (most plausibly for MDMA or psilocybin) would convert Arizona's research footing into a faster route to clinically supervised access, especially if the rescheduling that follows approval clears the controlled-substances barrier the vetoed 2024 and gutted 2025 service-center bills could not overcome at the state level. Absent FDA approval, Arizona patients have no legal access regardless of federal fast-tracking. (Marijuana Moment psychedelics, LegiScan SB1555)

Harm reduction faces direct federal exposure. SAMHSA guidance issued April 24, 2026 bars federal funds for fentanyl test strips, sterile syringes, smoking supplies, sterile water, and overdose hotlines, while still supporting naloxone, sharps disposal, and infectious-disease testing. Arizona legalized syringe services programs (SB1250) and fentanyl test strips (SB1486) in 2021, so these activities remain lawful under state law; the federal change attacks their funding, not their legality. Arizona programs run by cities, counties, and nongovernmental organizations that rely on federal pass-through dollars (including SAMHSA block-grant and grant funding administered through AHCCCS and county health departments) must now backfill test strips, syringes, and sterile water from state, county, local, or private sources or curtail those services, while naloxone distribution remains federally supportable. The guidance also creates a two-tiered carve-out under which law enforcement, medical workers, and public health officials may still buy test strips for professional duties, leaving direct-to-user distribution the exposed category. (SAMHSA guidance coverage / NACo, STAT, AZPHA, AHCCCS naloxone)

Fentanyl: the HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, hardening federal supply-side enforcement that runs alongside Arizona's status as a major fentanyl trafficking corridor; this is an enforcement backdrop rather than a state-policy lever, but it sits in tension with the SAMHSA defunding of the demand-side harm-reduction tools Arizona has authorized.

Patient access and rights

This section covers what Arizona law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Arizona has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Arizona is not among them. The absence is the finding: an Arizona patient has no enforceable right to use their medicine in a hospital today.

Broader protections: here Arizona is comparatively strong. A single statute, A.R.S. Section 36-2813, protects a registered qualifying patient across all six areas. It bars employment discrimination based solely on registry status or a positive test (with limited exceptions), bars a landlord or a school from refusing a person solely for being a patient, protects custody and visitation absent a demonstrated danger to the child, and provides that for the purposes of medical care, including organ transplants, authorized use is treated as the equivalent of any other prescribed medication. That last clause means an Arizona patient cannot be denied a place on a transplant list solely for lawful medical cannabis use.

Out-of-state patients: Arizona recognizes a visiting patient's possession only. A valid out-of-state medical card lets a visitor possess, but not purchase, at an Arizona dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Arizona has not enacted a Ryan's Law. The broader protections above are a creature of Arizona law, not federal law.

Sources: Arizona patient protections, A.R.S. Section 36-2813.

Analysis: the enclosure read in depth

Arizona is one of the more tightly fenced cannabis markets in the country, and the 2026 federal moves mostly tighten the fence rather than loosen it. The structural enclosure is built at the state level: a hard cap near 169 marijuana establishment licenses, mandatory vertical integration that forces any licensee to stand up cultivation, manufacturing, and retail at once, and a ban on intoxicating hemp outside that licensed system. Each of these is a barrier to entry that favors incumbents with capital and forecloses small, independent, and informal actors. The clearest evidence of capture is the social-equity program: of the 26 equity licenses awarded by lottery in 2022, reporting and litigation indicate corporate investors and operators came to control nearly all of them, with as few as three original winners retaining a stake, frequently through option and financing agreements signed before licenses even issued. A program designed to widen ownership instead became a conduit for consolidating it, and reform legislation to claw back improperly obtained licenses has not succeeded.

The state-plus-federal interaction sharpens this. The April 2026 Schedule III order hands a real tax benefit, 280E relief, to the medical category, but in Arizona's vertically integrated, MSO-heavy market that benefit accrues most to the players large enough to segregate, document, and DEA-register a compliant medical operation; the same players best positioned to absorb the new Schedule III compliance costs and the continued cash burden of stalled SAFER Banking. Recreational operations, where most volume and revenue sit, get no 280E relief at all. So the federal order does not democratize the market; it rewards scale and sophistication, deepening the incumbent advantage the state structure already created. The hemp cliff points the same direction: it eliminates the one channel, intoxicating hemp sold outside dispensaries, through which small and informal sellers could reach consumers without a scarce, expensive license, and it kills the SB1702 path to a separate legal hemp tier. The SAMHSA harm-reduction cuts, while not a market-structure lever, fit the broader federal posture of medicalize-and-control: institutional and professional actors keep access and funding, while direct-to-user services that reach the most marginalized lose their federal support. Read together, the federal enclosure favors large incumbents and fences out small and informal actors and hemp, reinforcing the same dynamic Arizona built into state law.

What to watch: whether the June 29, 2026 DEA rescheduling hearing (possibly slipping to 2027) moves toward broader Schedule III, which would extend 280E relief to recreational operators but still would not legalize, bank, or open interstate commerce; whether Treasury grants retrospective 280E relief to medical operators, a windfall that would again favor those with the accounting capacity to claim it; whether SAFER Banking revives; whether Arizona backfills the defunded harm-reduction supplies from state or county sources; whether the Psilocybin Advisory Board outputs and any FDA psychedelic approval reopen a state access debate; and whether a Prop 207 commercial-repeal initiative re-emerges for 2028 after the 2026 effort was abandoned.

The commons counter-moves are real but narrow. The protected six-plant home grow (twelve per household) is the single most important decentralizing feature: it is entrenched by the Voter Protection Act, survives even the abandoned 2026 repeal design, and gives every adult a lawful, license-free, non-commercial supply path that no federal lever touches. Petition-based expungement of qualifying marijuana offenses under Prop 207 is a second commons feature, though its non-automatic, file-it-yourself design limits reach to those who know about it and can navigate it. These carve-outs are why Arizona is not a maximal 5. But they sit beside a commercial market that is capped, vertically integrated, MSO-dominated, equity-captured, hemp-foreclosed, banking-starved, and now federally sorted in ways that reward the largest players. The state enclosure is severe and the 2026 federal dynamics reinforce rather than relieve it, with the only meaningful openness confined to non-commercial personal use. That balance, a heavily consolidated and fenced commercial market against a protected but strictly personal-use commons, justifies an enclosure score of 4/5: short of total enclosure only because home cultivation and possession remain genuinely and durably open.

Active legislation (2026)

The 2026 regular session ran from January 12, 2026, and adjourned in mid-June 2026, so most 2026 bills have reached a final disposition. The table below reflects significant 2025-2026 measures. This list is not exhaustive; for the long tail and live status, see the trackers linked below.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

I-04-2026 Sensible Marijuana Policy Act (repeal most of Prop 207 commercial market) (Filed Dec 2025, abandoned May 2026 (will not appear on ballot))
SB1287 (2025) Psilocybin service centers; licensure (Passed Senate 23-4 (Mar 2025), gutted in committee; service-center provisions removed)
Marijuana nuisance (smoke/odor) expansion Treats excessive marijuana smoke/odor as residential nuisance (Final enactment unconfirmed)

Bill	Title/Topic	Chamber	Status	Sponsor(s)
I-04-2026	Sensible Marijuana Policy Act (repeal most of Prop 207 commercial market)	Citizen initiative	Filed Dec 2025, abandoned May 2026 (will not appear on ballot)	Sean Noble / American Encore
SB1555 (2025)	Psilocybin advisory board	Senate	Signed into law June 27, 2025 (Ch. 231)	unconfirmed (advanced by psychedelics-reform coalition)
HB2871 (2025)	Ibogaine clinical research; 5M dollar appropriation	House	Signed into law	Rep. Wilmeth (per AZ House news releases)
SB1287 (2025)	Psilocybin service centers; licensure	Senate	Passed Senate 23-4 (Mar 2025), gutted in committee; service-center provisions removed	Sen. T. J. Shope (R)
SB1702 (2025)	Hemp-derived products; regulation	Senate	Introduced, dead	unconfirmed (HITA-backed)
Marijuana nuisance (smoke/odor) expansion	Treats excessive marijuana smoke/odor as residential nuisance	unconfirmed	Final enactment unconfirmed	unconfirmed

Live trackers: LegiScan Arizona, Arizona Legislature (azleg.gov), Marijuana Moment Arizona coverage, AZ Cannabis News. I could not independently confirm a 2026 bill number, sponsor, or final status for the marijuana nuisance measure; treat that row as unconfirmed pending the trackers.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →